Accordingly, IKZF1 gene deletions and variants in ALL patients impair a number of processes, including pre-BCR signaling, cell adhesion, proliferation and epigenetic signaling, metabolic and B/T-cell generation pathways, signal transduction, and cell surface receptor signaling. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.